VERAXA Biotech (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention.
The BiTAC-ADC platform represents a novel approach to antibody-drug conjugates, enabling localized activation of cytotoxic agents within the tumor microenvironment. This could reduce systemic side effects commonly associated with traditional chemotherapy. The BiTAC-TCE platform, a bispecific T cell engager, redirects immune cells to attack cancer cells. Combined, these platforms offer VERAXA a broad toolkit for addressing solid tumors, which have historically been challenging to treat with immunotherapies.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). The company is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. The new data further validates the company's quality-by-design approach to drug development.
For more details, the full press release is available at https://ibn.fm/r8zEz. Additional information about VERAXA and its technologies can be found in the company's newsroom at https://ibn.fm/VRXA.
The BIO International Convention provides a key venue for VERAXA to engage with potential partners. By showcasing these platforms, the company aims to accelerate the development of novel cancer therapies that could improve outcomes for patients with solid tumors.
